Discover the Science of Health
Last month, the National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
In a move that promotes open science, Johnson & Johnson (J&J) announced last week that it will make all of its clinical trial data publicly available.
A recent analysis shows that the National Institutes of Health (NIH) budget, adjusted for inflation, was $6 billion less in 2013 than it was ten years ago, and the number of research grants awarded by the NIH has fallen to the lowest level in 15 years.
The omnibus budget deal approved by House and Senate appropriations committees last week only partially restores biomedical research funds cut by the sequestration.
Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
